Back to drug

The Drug-Induced Respiratory Disease Website

This includes classic presentations of pulmonary TB and miliary tuberculosis which can be severe or fatal. A search for extrapulmonary TB is indicated in all cases. Drug-associated TB can occur via reactivation of prior latent TB or it is newly acquired. TB can be pulmonary, thoracic, extrathoracic or disseminated. See also under XVIIf, XVIIh, XVIIi

Publications

Charpy F, Altwegg R, Debourdeau A

Disseminated tuberculosis in a patient treated with tofacitinib for ulcerative colitis.

Journal of Crohn's & colitis 2021 Nov 09;; — 2021 Nov 09

Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, Kwok K, Lukic T, Mortensen E, Ponce de Leon D, Riese R, Valdez H

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.

Annals of the rheumatic diseases 2016 Jun;75;1133-8 — 2016 Jun — 1133-8

van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B,

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

The New England journal of medicine 2012 Aug 09;367;508-19 — 2012 Aug 09 — 508-19

Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS,

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.

The New England journal of medicine 2012 Aug 09;367;495-507 — 2012 Aug 09 — 495-507

Maiga M, Lun S, Guo H, Winglee K, Ammerman NC, Bishai WR

Risk of tuberculosis reactivation with tofacitinib (CP-690550).

The Journal of infectious diseases 2012 Jun;205;1705-8 — 2012 Jun — 1705-8